OrbiMed Advisors leads Series A round for Clementia Pharmaceuticals
Clementia Pharmaceuticals has raised $22.5 million in Series A financing. OrbiMed Advisors led the round with participation from return backer BDC Venture Capital. Clementia has also agreed to acquire the global rights to palovarotene, a retinoic acid receptor gamma agonist from Roche Pharmaceuticals. No financial terms were disclosed. Based in Quebec, Clementia Pharmaceuticals is a biotech company focused on developing a treatment for Fibrodysplasia Ossificans Progressiva.
10 January 2014•5 mins read
